Elevated Fecal and Serum Calprotectin in COVID-19 Are not Consistent With Gastrointestinal Symptoms

Hajar Shokri-Afra ©, Hemen Moradi-Sardareh , Bahman Moradipoodeh, Ahmad Alikhani, Hafez Fakheri

Elevated Fecal and Serum Calprotectin in COVID-19 Are not Consistent With Gastrointestinal Symptoms

کد: G-75890

نویسندگان: Hajar Shokri-Afra ©, Hemen Moradi-Sardareh , Bahman Moradipoodeh, Ahmad Alikhani, Hafez Fakheri

زمان بندی: زمان بندی نشده!

برچسب: سایر

دانلود: دانلود پوستر

خلاصه مقاله:

Background and Aim

Intestinal epithelial cell damage caused by SARS-CoV-2 infection was thought to be associated with gastrointestinal symptoms and decreased fecal consistency. The association of the gastrointestinal symptoms with the COVID-19-mediated inflammatory response triggered by the gastrointestinal immune system was investigated in this paper.

Methods

Intestinal inflammation marker fecal calprotectin along with serum calprotectin and other inflammatory markers were measured in COVID-19 cases with and without GI manifestations as well as healthy individuals. Analyses were performed to compare COVID-19 patient subgroups and healthy controls and examine the relationship between fecal and serum calprotectin levels with gastrointestinal symptoms and disease severity.

Results

COVID-19 patients (n = 70) were found to have markedly elevated median levels of fecal (124.3 vs. 25.0 µg/g; P less than 0/0001) and serum calprotectin (3500 vs. 1060 ng/mL; P less than 0/0001) compared with uninfected controls. Fecal and serum calprotectin levels were not significantly different between COVID-19 patients who displayed GI symptoms and those who did not. Compared with other acute phase markers, both fecal and serum calprotectin were superior in identifying COVID-19 patients who progressed to severe illness.

Conclusion

Although the progression of COVID-19 disease is marked by an elevation of fecal and serum calprotectin, gastrointestinal symptoms or diarrhea were not correlated with calprotectin increase level.

Keywords

Biomarkers; COVID-19; Calprotectin; Diarrhea; Gastrointestinal Diseases; Inflammation

دیدگاه ها (0)

تاکنون دیدگاهی منتشر نشده است. شما اولین نفر باشید!

ارسال یک دیدگاه

ارسال دیدگاه توسط مدیریت بسته شده است.